Lancet: Arteju monoantial is used in complementary chemotherapy for early triple negative breast cancer.

Currently, first-line new complementary chemotherapy options for patients with early triple-negative breast cancer (TNBC) include cyclocycline-cyclophosphamide and yew alkane chemotherapy.
in the IMpassion031 study, the researchers looked at the effectiveness of Artetin monoantigen-binding yew alcohol-amycin-cyclophosphamide as a new complementary treatment for early TNBC.
This Phase III clinical study was conducted at 75 medical centers in 13 countries, involving untreated Phase II-III TNBC patients over the age of 18, in albumin-binding yew alcohol (125mg/m2, once a week for 12 weeks) - amycin (60mg/m 2, 1 every 2 weeks, lasts 8 weeks) - Cyclophosphamide (600 mg/m 2, 1 every 2 weeks, lasts 8 weeks) on the basis of treatment, randomly received 840mg attain or placebo, 1 every 2 weeks.
end point of the study was pathological complete response.
333 patients were involved in the study, including 165 in the Arteju monoantin group and 168 in the placebo group.
20.6 months in the art-pearl monoanto-resistance group and 19.8 months in the placebo group.
95 patients in the articulate monomathic group achieved a complete response to histological pathology, and in the placebo group 69 (58% vs 41%).
in the PD-L1-positive subgroup, 69% of patients in the Attju monoantin group achieved a complete response to histological pathology, and 49% in the placebo group.
the study period, 37 patients in the attentive monotherapy group had severe adverse events associated with treatment at level 3-4, 26 cases in the placebo group (23% vs 16%), and 1 patient in each group had level 5 adverse events.
study concluded that for early triple-negative breast cancer patients, Artejumodant-albumin-binding yew alcohol-amycin-cyclophosphamide therapy can significantly improve histological pathological response.
.